COVID-19 is the pandemic disease caused by the SARS-CoV-2 coronavirus. It is a highlycontagious viral disease, the condition of which main clinical symptoms are characterizedby fever and respiratory symptoms. Evidence indicates to worse outcomes in patients withpre-existing diseases, such as diabetes, arterial hypertension, heart disease,pneumopathies, chronic kidney disease, and immunodeficiencies. Recipients of kidneytransplants make prolonged use of immunosuppressive drugs to inhibit the acquired immuneresponse, notably the activity of lymphocytes. Due to this potential to modulate theimmune and inflammatory response, it is speculated that the clinical and laboratorycondition of COVID-19 in these patients is atypical. Preliminary evidence suggests worseoutcomes of COVID-19 in immunosuppressed patients, as carriers of cancer. However,information on kidney transplant recipients is insufficient. So far, only reports of thecase are available in the literature with different clinical presentations and outcomes.The aim of this study is, therefore, to characterize the demographics, clinical andlaboratory conditions, and the outcomes of COVID-19 in kidney transplant recipients in anational multicenter cohort.
COVID-19 is the pandemic disease caused by the SARS-CoV-2 coronavirus. It is a highly
contagious viral disease, the condition of which main clinical symptoms are characterized
by fever and respiratory symptoms. Evidence indicates to worse outcomes in patients with
pre-existing diseases, such as diabetes, arterial hypertension, heart disease,
pneumopathies, chronic kidney disease, and immunodeficiencies. Recipients of kidney
transplants make prolonged use of immunosuppressive drugs to inhibit the acquired immune
response, notably the activity of lymphocytes. Due to this potential to modulate the
immune and inflammatory response, it is speculated that the clinical and laboratory
condition of COVID-19 in these patients is atypical. Preliminary evidence suggests worse
outcomes of COVID-19 in immunosuppressed patients, as carriers of cancer. However,
information on kidney transplant recipients is insufficient. So far, only reports of the
case are available in the literature with different clinical presentations and outcomes.
The aim of this study is, therefore, to characterize the demographics, clinical and
laboratory conditions (mechanical ventilation, need for dialysis, need for ICU admission
during evolution) and the outcomes of COVID-19 (death and graft loss within 3 months
after infection up to 3 months after resolution) in kidney transplant recipients in a
national multicenter cohort.Inclusion Criteria:1. Kidney transplant recipients, which may
be multi-organ recipients, transplanted in any follow-up period; 2. Positive diagnostic
test for COVID-19 (detection of viral load, test for detection of antigens or tests for
detection of antibodies); 3.Outpatient or hospital management; 4.Adults and children.
Exclusion Criteria: None
Inclusion Criteria:
1. Kidney transplant recipients, which may be multi-organ recipients, transplanted in
any follow-up period;
2. Positive diagnostic test for COVID-19 (detection of viral load, test for detection
of antigens or tests for detection of antibodies);
3. Outpatient or hospital management;
4. Adults and children.
Exclusion Criteria:
-
Hospital do Rim
São Paulo, Aão Paulo, Brazil
Helio Tedesco
+55 11 5087-8113
heliotedesco@medfarm.com.br
Monica Nakamura
+55 11 5087 8318
Jose Osmar Medina, Study Director
Hospital do Rim